Paul K

I’ll never get sick of Sting just stuck, trapped listening to someone slaughtering his music. He’s marinating in agony and embarrassment!

Here is the Sun's pitifully small apology for its lie about benefits tourism - a lie that was accepted as truth by millions and helped deliver Brexit. These lies are perverting our democracy. At a minimum, apologies should be published in the same location and size as the lie.

This is HUGE Can you help get this story out there?? Let's RT this 10,000 times!!!

We are delighted to announce a further £1.2 million of Innovate UK Launchpad funding to be released this month for businesses with ambition for growth and working in life and health sciences. Find out more lnkd.in/eryn9336HIRANI & register your interest lnkd.in/eewfjsGN

@LifeSciVC @atlasventure Congratulations on the 20 year anniversary!

Twenty years ago in mid-October 2005, I joined @AtlasVenture. Hard to believe - time flies. A big thank you to my partners JF Formela and Peter Barrett, who took a bet on me. Both have been great mentors, partners, and friends. Since 2005, I've worked with hundreds of incredible people around the Atlas ecosystem and dozens of biotech startups... So to celebrate this milestone, I've done some fun reflecting on my observations of biotech venture... and will have three blogs out this week. Tuesday, Part 1: I'll share my thoughts on a few Science/R&D topics relevant for biotech startups. Wednesday, Part 2: People topics, like working with CEOs and more. Thursday, Part 3: Business - including corporate development, boards, and syndicates. So much more I'd love to share, but 6000+ words across three blogs is plenty!

I think that @BBCNews, @SkyNews @ITVNewsPolitics and @Channel4News should all be reporting on Reform UK and Russian bribery. RT if you agree!! Why are the media ignoring such a blatant story?!

I love the idea that she ‘checked’

Cancer cachexia = an underdiagnosed, lethal syndrome. · Affects up to 80% in pancreatic CA, 40% in lung. · It’s not just weight loss—think systemic inflammation, altered metabolism, fat/muscle wasting. · GDF-15, IL-6, activin A are key molecular drivers. · A major unmet need in cancer patients aacrjournals.org/cancerdiscover…

Absolutely fantastic news 👏 At all levels, commercialisation of good science, great teams both scientistifically and investment and great outcomes for patients and the pharma industry!

Patent cliff pushing pharma companies earlier in deal making $XBI $IBB good summary by the FT

🧬 The Future of Antibody-Drug Conjugates (ADCs): 2025-2035 ADCs are hitting their stride. From 15 approvals today to 40+ by 2035, they’re becoming one of the most powerful therapeutic platforms in biotech. Here’s a year-by-year breakdown of what’s coming next 👇🏼

Great to see the UK Government’s Life Sciences Sector Plan published, which looks to harness UK science and innovation, strengthen the NHS and drive long-term economic growth. The UK Government’s ambition is that the UK will be the leading life sciences economy in Europe by 2030 and the third most important globally by 2035. In particular, it was great to read of the UK Government’s particular focus on innovative medicines that reduce hospital admissions. See this in Action 28: Reduce friction in the system to optimise access and uptake of new #drugs – on page 38. POLB 001, our preventative therapy targets cancer immunotherapy-induced CRS and can potentially reduce or remove the need for patient hospitalisation when receiving cancer immunotherapy treatment. Full report published here: gov.uk/government/pub… #POLB #Healthcare #10yearPlan #LifeSciences #UK #NHS #Hospitalisations #CRS #Treatments

17 million people just lost health care. 18 million kids just lost school meals. 3 million Americans just lost food assistance. And $3.5 trillion was added to the deficit. All for a tax cut for Trump’s billionaire donors. The ultimate betrayal.

CITY OF DERRY WALK - NOW ON A SUNDAY Join us on Sunday 14th September for a beautiful walk along the banks of the river Foyle. The perfect opportunity to get together with family and friend to help us mark blood cancer awareness month. llni.co.uk/event/city-of-… #BCAM2025

Great to see such progress, but we have a lot of work to do for patients with lung, oesphageal, liver and pancreatic cancers. Reflects the absolute importance of #ClinicalTrial in improving outcomes @cancertrials_ie @CancerInstIRE @IRROGTrials @IrishCancerSoc

"Brexit has ruined this country, and now the majority of Britons thinks so too." RT if you are that majority.

Pitchbook data on biotech fund raises by year via @biospace. No wonder we've felt the pain of coming off 2018-2019 but it's looking quite anaemic now.

Great article Cormac on the promise of exciting breakthrough treatments for cancer.

Individualized #cancer #vaccines targeting #neoantigens have shown promise in small-scale studies, but the field is waiting on data from Merck's & Moderna's phase 3 trial of the #mRNA vaccine Intismeran autogene in #melanoma. Just out in @NatureBiotech nature.com/articles/s4158…

@andrewpannu Thanks for sharing @andrewpannu

Big Pharma M&A and licensing deal trends in 2025 Amidst turbulent markets, we've still seen robust activity. Some key stats: • 38 total deals (31 licensing and 7 M&A) • ~$60B in total deal volume (~$33B in licensing and ~$27B in M&A) • By volume, ~68% of deal assets were early-stage (PC - Ph1/2); by $ value, it was ~48% • Unsurprisingly, Oncology (~37%) was the most popular TA • ~55% were small molecules On that last point, while (for now) the IRA still seems to incentivize biological development given the shorter exemption period (9 vs. 13 years), we haven't seen as big of an impact on deal activity as initially feared. These assets have less manufacturing risk, can be seamlessly integrated into existing commercial infrastructure and can be favored by patients due to their convenient dosing, typically oral. So what has been driving Pharma M&A thus far? • LOEs: Pharma is staring down ~$100B in LOEs through 2028 (~7% of total worldwide revenue). This all needs to be replaced which necessitates more dealmaking. Of note, the companies most exposed to upcoming LOEs (Merck, BMS, AZ, etc.) tended to be more focused on later-stage (Ph2+) assets • Compelling valuations and demand for strategic exits: the broader equity market drawdown has pulled biotech into an even deeper slump, cratering public valuations and tempering late-stage financings. Broad investor enthusiasm will likely stay muted for now, meaning more biotech management teams will need to come to terms with their valuation and seek M&A as their primary exit strategy • Compelling science: of course, all of these market dynamics are against the backdrop of compelling innovation. There will always be appetite within Pharma for best-in-class assets with blockbuster potential Let me know in the comments if you'd like a hi-res PDF copy of the graphic, happy to send that across. And if you're a Pharma BD or Strategy leader and have made it this far - here's a gift 👇 If you're looking for market intelligence insights like this, but tailored to your strategic priorities and delivered to your inbox in real-time, DM me! We've pulled together a short list of industry leaders that get robust analyses on autopilot based on their preferences and we're adding a few more slots.